GH Research (NASDAQ:GHRS - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright's price target would indicate a potential upside of 352.74% from the stock's previous close.
Separately, Canaccord Genuity Group decreased their price target on GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research note on Monday, November 18th.
Check Out Our Latest Stock Analysis on GH Research
GH Research Price Performance
Shares of GH Research stock traded up $0.01 during trading on Monday, hitting $8.84. The company's stock had a trading volume of 57,627 shares, compared to its average volume of 93,419. The stock has a market cap of $459.67 million, a price-to-earnings ratio of -11.18 and a beta of 0.84. GH Research has a 52 week low of $6.00 and a 52 week high of $14.99. The stock has a 50-day moving average price of $8.42 and a two-hundred day moving average price of $8.96.
Institutional Investors Weigh In On GH Research
An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. grew its holdings in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,686,689 shares of the company's stock after buying an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 56.90% of the company's stock.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Further Reading
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
